A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

Source:http://linkedlifedata.com/resource/pubmed/id/11606381

Cancer Res. 2001 Oct 15 61 20 7464-72

Download in:

View as

Triples

General Info

PMID
11606381